Hypertension, proteinuria, and antagonism of va... [J Clin Oncol. 2007] - PubMed

loading

Hypertension and proteinuria: a class-effect of antiangiogenic therapies. [Anticancer Drugs. 2009]
Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V, Deray G. Anticancer Drugs. 2009 Jan; 20(1):81-2.
Review Vascular endothelial growth factor (VEGF) inhibition by small molecules. [J Chemother. 2004]
Review Vascular endothelial growth factor (VEGF) inhibition by small molecules.
Ahmed SI, Thomas AL, Steward WP. J Chemother. 2004 Nov; 16 Suppl 4:59-63.
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. [Expert Rev Anticancer Ther. 2009]
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH, Tzakos A, Zografos G. Expert Rev Anticancer Ther. 2009 Oct; 9(10):1413-6.
Review Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. [Cancer Treat Rev. 2011]
Review Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D. Cancer Treat Rev. 2011 Aug; 37(5):344-52. Epub 2011 Mar 23.
Review Management of hypertension in angiogenesis inhibitor-treated patients. [Ann Oncol. 2009]
Review Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Ann Oncol. 2009 May; 20(5):807-15. Epub 2009 Jan 15.

Review Targeting angiogenesis in gynecologic cancers. [Hematol Oncol Clin North Am. 2...]
Review Targeting angiogenesis in gynecologic cancers.
Zand B, Coleman RL, Sood AK. Hematol Oncol Clin North Am. 2012 Jun; 26(3):543-63, viii.
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. [Clin Exp Pharmacol Physiol. 2012]
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Nagasawa T, Hye Khan MA, Imig JD. Clin Exp Pharmacol Physiol. 2012 May; 39(5):454-61.
Review Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. [PLoS One. 2011]
Review Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Lima AB, Macedo LT, Sasse AD. PLoS One. 2011; 6(8):e22681. Epub 2011 Aug 2.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor ...
Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
J Clin Oncol. 2007 Jul 20 ;25(21):2993-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed